Supporting Decisions in Cancer
ENOX2
NEW Marker for Early Cancer Detection & Monitoring

The most common question asked by every patient with a serious chronic disease:  

"Is my Treatment Working"?

Answering that question with accuracy and confidence is one of the most complex challenges clinicians face.

QuickLab Corporation provides the only source for quantitative ENOX2 ELISA testing world-wide, helping physicians answer critical-path questions quickly and cost-effectively.  The ENOX2 marker promotes trend analysis and timely decision-making insights for implementing mid-course therapeutic modifications unlike anything available before.  Furthermore, the ENOX2 test for establishing a baseline during routine examinations.

 

 These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure, or prevent any disease.